Watson launches BPH drug Rapaflo in US
This article was originally published in Scrip
Executive Summary
Watson Pharmaceuticals has launched its orally active alpha 1a-adrenoceptor selective antagonist Rapaflo (silodosin) in the US for the treatment of benign prostatic hyperplasia (BPH) following an FDA approval last October.